Thomas Weber

List of Publications by Year
in descending order

69 papers	7,204 citations	109321 35 h-index	110387 64 g-index
71 all docs	71 docs citations	71 times ranked	6114 citing authors

#	Article	IF	Citations
1	Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Therapy, 2021, 28, 683-696.	4.5	37
2	Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions. Frontiers in Immunology, 2021, 12, 658399.	4.8	84
3	CMT2N-causing aminoacylation domain mutants enable Nrp1 interaction with AlaRS. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	16
4	Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. Circulation, 2021, 144, 52-73.	1.6	38
5	Hydroxylation of N-acetylneuraminic Acid Influences the in vivo Tropism of N-linked Sialic Acid-Binding Adeno-Associated Viruses AAV1, AAV5, and AAV6. Frontiers in Medicine, 2021, 8, 732095.	2.6	3
6	Effects of genetic transfection on calcium cycling pathways mediated by double-stranded adeno-associated virus in postinfarction remodeling. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 1809-1819.e3.	0.8	12
7	Intratracheal Gene Delivery of SIN3A Inhibits Pulmonary Arterial Hypertension and Restores BMPR2 Expression. , 2020, , .		0
8	Identification of Genes and Pathways Regulated by Lamin A in Heart. Journal of the American Heart Association, 2020, 9, e015690.	3.7	9
9	Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption. Molecular Therapy - Methods and Clinical Development, 2020, 16, 192-203.	4.1	48
10	Abstract 13932: Lung-targeted Sin3a Gene Therapy as a Promising Strategy to Restore Bmpr2 Expression in Pulmonary Arterial Hypertension. Circulation, 2020, 142, .	1.6	0
11	3213 Unraveling the role of Phospholamban (PLN) in humans via the characterization of Induced Pluripotent Stem Cell (iPSC) Cardiomyocytes (CM) derived from carriers of a lethal PLN mutation. Journal of Clinical and Translational Science, 2019, 3, 26-26.	0.6	0
12	Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer. Journal of Cardiovascular Development and Disease, 2019, 6, 8.	1.6	19
13	AAV Vectors for Efficient Gene Delivery to Rodent Hearts. Methods in Molecular Biology, 2019, 1950, 311-332.	0.9	5
14	Protein S Protects against Podocyte Injury in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 1397-1410.	6.1	34
15	A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity. Human Gene Therapy, 2018, 29, 927-937.	2.7	10
16	Human Cardiac Gene Therapy. Circulation Research, 2018, 123, 601-613.	4.5	75
17	Cardiac gene therapy with adeno-associated virus-based vectors. Current Opinion in Cardiology, 2017, 32, 275-282.	1.8	42
18	Production and Characterization of Vectors Based on the Cardiotropic AAV Serotype 9. Methods in Molecular Biology, 2017, 1521, 91-107.	0.9	18

#	Article	IF	Citations
19	Do we need marker gene studies in humans to improve clinical AAV gene therapy?. Gene Therapy, 2017, 24, 72-73.	4.5	3
20	Protein Phosphatase Inhibitor-1 GeneÂTherapy in a Swine Model of NonischemicÂHeart Failure. Journal of the American College of Cardiology, 2017, 70, 1744-1756.	2.8	30
21	Use of Adeno-Associated Virus Vector for Cardiac Gene Delivery in Large-Animal Surgical Models of Heart Failure. Human Gene Therapy Clinical Development, 2017, 28, 157-164.	3.1	27
22	Gene Therapy for Cardiovascular Diseases. , 2016, , 377-387.		0
23	Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids. Human Gene Therapy Methods, 2016, 27, 1-12.	2.1	111
24	Effectiveness of gene delivery systems for pluripotent and differentiated cells. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14067.	4.1	47
25	Syntaxin 5-Dependent Retrograde Transport to the <i>trans</i> -Golgi Network Is Required for Adeno-Associated Virus Transduction. Journal of Virology, 2015, 89, 1673-1687.	3.4	67
26	High Capsidâ€"Genome Correlation Facilitates Creation of AAV Libraries for Directed Evolution. Molecular Therapy, 2015, 23, 675-682.	8.2	25
27	Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure. Gene Therapy, 2014, 21, 379-386.	4.5	21
28	Alternatively Spliced Tissue Factor Promotes Plaque Angiogenesis Through the Activation of Hypoxia-Inducible Factor-1Î± and Vascular Endothelial Growth Factor Signaling. Circulation, 2014, 130, 1274-1286.	1.6	44
29	Gene Therapy: Charting a Future Courseâ€"Summary of a National Institutes of Health Workshop, April 12, 2013. Human Gene Therapy, 2014, 25, 488-497.	2.7	12
30	Cardiac I-1c Overexpression With Reengineered AAV Improves Cardiac Function in Swine Ischemic Heart Failure. Molecular Therapy, 2014, 22, 2038-2045.	8.2	70
31	Pre-existing Antiâ€"Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy. Human Gene Therapy Methods, 2013, 24, 59-67.	2.1	241
32	Response to â€˜Run for your life â€¦ at a comfortable speed and not too farâ€™. Heart, 2013, 99, 588.1-588.	2.9	8
33	Concomitant Intravenous Nitroglycerin With Intracoronary Delivery of AAV1.SERCA2a Enhances Gene Transfer in Porcine Hearts. Molecular Therapy, 2012, 20, 565-571.	8.2	34
34	Neutralizing Antibodies Against AAV Serotypes 1, 2, 6, and 9 in Sera of Commonly Used Animal Models. Molecular Therapy, 2012, 20, 73-83.	8.2	143
35	Quantification of AAV Particle Titers by Infrared Fluorescence Scanning of Coomassie-Stained Sodium Dodecyl Sulfateâ€"Polyacrylamide Gels. Human Gene Therapy Methods, 2012, 23, 198-203.	2.1	33
36	Novel Approaches to Deliver Molecular Therapeutics in Cardiac Disease Using Adeno-Associated Virus Vectors. , 2012, , 391-458.		1

#	Article	IF	Citations
37	Gene Therapy for Heart Failure. Circulation Research, 2012, 110, 777-793.	4.5	130
38	Intracellular transport of recombinant adeno-associated virus vectors. Gene Therapy, 2012, 19, 649-658.	4.5	190
39	Adeno-Associated Virus 2 Infection Requires Endocytosis through the CLIC/GEEC Pathway. Cell Host and Microbe, 2011, 10, 563-576.	11.0	151
40	Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Therapy, 2010, 17, 872-879.	4.5	54
41	Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction. Virology, 2007, 367, 10-18.	2.4	35
42	pH-Dependent Lytic Peptides Discovered by Phage Display. Biochemistry, 2006, 45, 6476-6487.	2.5	10
43	Altering AAV tropism with mosaic viral capsids. Molecular Therapy, 2005, 11, 856-865.	8.2	68
44	Reconstitution of Ca2+-Regulated Membrane Fusion by Synaptotagmin and SNAREs. Science, 2004, 304, 435-438.	12.6	346
45	Liposome Fusion Assay to Monitor Intracellular Membrane Fusion Machines. Methods in Enzymology, 2003, 372, 274-300.	1.0	59
46	Mutations in Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase Causing Increased Receptor Binding Activity and Resistance to the Transition State Sialic Acid Analog 4-GU-DANA (Zanamivir). Journal of Virology, 2003, 77, 309-317.	3.4	50
47	Regulation of membrane fusion by the membrane-proximal coil of the t-SNARE during zippering of SNAREpins. Journal of Cell Biology, 2002, 158, 929-940.	5.2	194
48	A putative link between exocytosis and tumor development. Cancer Cell, 2002, 2, 427-428.	16.8	14
49	Vitamin E analogues as inducers of apoptosis: implications for their potential antineoplastic role. Redox Report, 2001, 6, 143-151.	4.5	48
50	Identification of synapsin I peptides that insert into lipid membranes. Biochemical Journal, 2001, 354, 57.	3.7	34
51	Identification of synapsin I peptides that insert into lipid membranes. Biochemical Journal, 2001, 354, 57-66.	3.7	61
52	Functional architecture of an intracellular membrane t-SNARE. Nature, 2000, 407, 198-202.	27.8	222
53	Use of Affinity Chromatography and TID-Ceramide Photoaffinity Labeling for Detection of Ceramide-Binding Proteins. Methods in Enzymology, 2000, 312, 429-438.	1.0	4
54	Close Is Not Enough. Journal of Cell Biology, 2000, 150, 105-118.	5.2	285

#	Article	IF	Citations
55	Snarepins Are Functionally Resistant to Disruption by Nsf and Î±SNAP. Journal of Cell Biology, 2000, 149, 1063-1072.	5.2	113
56	Putative fusogenic activity of NSF is restricted to a lipid mixture whose coalescence is also triggered by other factors. EMBO Journal, 2000, 19, 1272-1278.	7.8	32
57	Ceramide as an Activator Lipid of Cathepsin D. , 2000, 477, 305-315.		102
58	Content mixing and membrane integrity during membrane fusion driven by pairing of isolated v-SNAREs and t-SNAREs. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 12571-12576.	7.1	176
59	Rapid and efficient fusion of phospholipid vesicles by the alpha -helical core of a SNARE complex in the absence of an N-terminal regulatory domain. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 12565-12570.	7.1	249
60	The Length of the Flexible SNAREpin Juxtamembrane Region Is a Critical Determinant of SNARE-Dependent Fusion. Molecular Cell, 1999, 4, 415-421.	9.7	154
61	Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO Journal, 1999, 18, 5252-5263.	7.8	320
62	Identification of intracellular ceramide target proteins by affinity chromatography and TID-ceramide photoaffinity labelling. Biochemical Society Transactions, 1999, 27, 393-399.	3.4	8
63	SNAREpins: Minimal Machinery for Membrane Fusion. Cell, 1998, 92, 759-772.	28.9	2,289
64	The Myristoyl Moiety of Myristoylated Alanine-rich C Kinase Substrate (MARCKS) and MARCKS-related Protein Is Embedded in the Membrane. Journal of Biological Chemistry, 1995, 270, 19879-19887.	3.4	73
65	2-(Tributylstannyl)-4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzyl Alcohol: A Building Block for Photolabeling and Crosslinking Reagents of Very High Specific Radioactivity. Journal of the American Chemical Society, 1995, 117, 3084-3095.	13.7	96
66	Identification of Functional Domains in the Cytoskeletal Protein Talin. FEBS Journal, 1994, 224, 951-957.	0.2	65
67	Insertion of Filamin into Lipid Membranes Examined by Calorimetry, the Film Balance Technique, and Lipid Photolabeling. Biochemistry, 1994, 33, 12565-12572.	2.5	29
68	Evidence for H(+)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane. Journal of Biological Chemistry, 1994, 269, 18353-18358.	3.4	90
69	Evidence for H(+)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane. Journal of Biological Chemistry, 1994, 269, 18353-8.	3.4	79